2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10304
    Orbofiban 163250-90-6 98%
    Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban
  • HY-10307
    Roxifiban 170902-47-3 98%
    Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina.
    Roxifiban
  • HY-10314
    Lotrafiban 171049-14-2 98%
    Lotrafiban is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban
  • HY-10315
    Elarofiban 198958-88-2 98%
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
    Elarofiban
  • HY-10594
    Letaxaban 870262-90-1 98%
    Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases.
    Letaxaban
  • HY-10672
    Urotensin-II receptor antagonist-1 1034708-07-0 98%
    Urotensin-II receptor antagonist-1 (compound 1) is a low oral bioavailability (F=0-3%, rat) selective human Urotensin II receptor antagonist, Ki=16 nM (test on HEK293 cells expressing recombinant human UT receptor). Urotensin-II receptor antagonist-1 inhibits cytochrome P450 (IC50=0.75 μM, CYP2D6; 1.4 μM, CYP3A4), inhibits κ-opioid receptor (EC50=3.2 μM), targets cardiac sodium channels (Ki=2.5 μM).
    Urotensin-II receptor antagonist-1
  • HY-10722
    DX-9065a 155204-81-2 98%
    DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions.
    DX-9065a
  • HY-10724
    Fidexaban 183305-24-0 98%
    Fidexaban is a Factor Xa inhibitor and can be used in research of cardiovascular disease.
    Fidexaban
  • HY-10756
    BMS-740808 280118-23-2 98%
    BMS-740808 is a potent, selective and orally active factor Xa inhibitor with a Ki of 30 pM. BMS-740808 shows >1000-fold for factor Xa than other proteases.
    BMS-740808
  • HY-10758
    FXa-IN-1 441328-10-5 98%
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
    FXa-IN-1
  • HY-10777
    EMD 495235 811811-33-3 98%
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities.
    EMD 495235
  • HY-10780
    JTV-803 mesylate 247131-79-9 98%
    JTV-803 mesylate is a human factor Xa inhibitor with oral anticoagulant activity. JTV-803 exhibits competitive inhibition of human factor Xa, with a Ki value of 0.019μM and IC50Value is 0.081μM. JTV-803 is 100 times more selective at inhibiting human factor Xa than its comparator. JTV-803 is an effective oral anticoagulant for the prevention of thrombosis.
    JTV-803 mesylate
  • HY-10826
    DG051 free acid 929916-05-2 98%
    DG051 (free acid) is an effective inhibitor of leukotriene A4 hydrolase (LTA4H), with a Kd of 26 nM. It has high water solubility (greater than 30 mg/mL) and high oral bioavailability (over 80% across different species). DG051 (free acid) can be used in research related to myocardial infarction and stroke.
    DG051 free acid
  • HY-10833
    ROCK-IN-10 1038549-25-5 98%
    ROCK-IN-10 (compound 50) is a potent ROCK inhibitor with IC50 values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases.
    ROCK-IN-10
  • HY-12172
    MK-8141 903579-36-2 98%
    MK-8141 (ACT-077825) is a renin inhibitor that significantly increases levels of immunoreactive renin (ir-AR) by sevenfold but does not result in sustained reductions in blood renin activity (PRA). This study evaluated the antihypertensive efficacy of MK-8141 in hypertensive disease. Despite its effects on ir-AR, MK-8141 (ACT-077825) did not produce significant blood pressure-lowering effects in the absence of sustained PRA inhibition.
    MK-8141
  • HY-12174
    Zankiren 138742-43-5 98%
    Zankiren (A-72517) is an orally active inhibitor for renin. Zankiren exhibits renal vasodilator effect, through reduction of angiotensin II formation without affecting other vasodilator mechanisms.
    Zankiren
  • HY-12631
    BMS-654457 1004551-41-0 98%
    BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
    BMS-654457
  • HY-12995
    BI 665915 1360550-04-4 98%
    BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases.
    BI 665915
  • HY-13705
    NM-3 181427-78-1 98%
    NM-3 is an isocoumarin with antiarthritic and antiangiogenic effects. NM-3 is an orally active antiangiogenic agent with low toxicity.
    NM-3
  • HY-13708
    SUN C5174 191592-36-6 98%
    SUN C5174 is an antagonist for 5-HT2 receptor with a mild sympathomimetic efficacy. SUN C5174 attenuates disorders in various experimental models of peripheral circulatory disturbance, and exhibits good pharmacokinetic properties.
    SUN C5174
Cat. No. Product Name / Synonyms Application Reactivity